-
Nov 17, 2024 | 
jamanetwork.com | Orly Vardeny |Outcomes Research |Brian Claggett |Michele Senni
Key PointsQuestion
What is the treatment effect of finerenone, relative to placebo, in patients with heart failure with mildly reduced or preserved ejection fraction based on postrandomization potassium levels? Findings
Among 6001 patients in a clinical trial, finerenone increased potassium levels greater than 5.5 mmol/L and decreased potassium levels less than 3.5 mmol/L.
-
Oct 31, 2024 | 
jamanetwork.com | Brian Claggett |Kansas City |Felipe Martinez |Sheila M. Hegde
Key PointsQuestion When are the clinical benefits of the sodium glucose cotransporter 2 inhibitor dapagliflozin first apparent among patients with heart failure with mildly reduced or preserved ejection fraction?
-
Oct 22, 2024 | 
onlinelibrary.wiley.com | Henri Lu |Brian Claggett |Milton Packer |Baylor Heart
Supporting Information Filename Description ejhf3487-sup-0001-Figures.docxWord 2007 document , 1.3 MB Appendix S1. Supporting Information. References 1, , , , , , et al.; CHARM Investigators. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: Results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol 2012; 59: 1785–1795.
-
Oct 11, 2024 | 
jacc.org | Jawad H. Butt |Alasdair Henderson |Pardeep S. Jhund |Brian Claggett
Introduction Aldosterone is secreted by the adrenal glands and regulated by circulating angiotensin II and serum potassium concentration, and the deleterious consequences of excessive production of this hormone (and mineralocorticoid receptor overactivation) on the heart, vasculature, and kidney are well-established.1-5 However, aldosterone synthase is also expressed in adipocytes, which can secrete aldosterone, and angiotensin II is produced in adipose tissue and stimulates the production of...
-
Oct 9, 2024 | 
jacc.org | Muthiah Vaduganathan |Brian Claggett |Ian J. Kulac |Akshay S. Desai
AbstractBackgroundFinerenone has kidney protective effects in patients with chronic kidney disease (CKD) with type 2 diabetes, but effects on kidney outcomes in patients with heart failure (HF) with and without diabetes and/or CKD are not known. ObjectivesExamine the effects of finerenone on kidney outcomes in FINEARTS-HF, a randomized trial of finerenone vs. placebo among patients with HF with mildly reduced or preserved ejection fraction.
-
Oct 1, 2024 | 
jacc.org | Safia Chatur |Iris E. Beldhuis |Brian Claggett |Finnian McCausland
References1. "Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis". Eur Heart J . 2014;35:455-469. https://doi.org/10.1093/eurheartj/eht386. 2. "Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function". Circ Heart Fail . 2017;10:8: e003825 https://doi.org/10.1161/circheartfailure.116.003825. 3.
-
Sep 30, 2024 | 
jamanetwork.com | Brian Claggett |Muthiah Vaduganathan |Akshay S. Desai |Pardeep S. Jhund
Key PointsQuestion Do the effects of dapagliflozin on cardiovascular events vary according to baseline kidney function, and does dapagliflozin reduce the rate of estimated glomerular filtration rate (eGFR) decline and kidney outcomes among patients with heart failure and mildly reduced or preserved ejection fraction?
-
Sep 29, 2024 | 
jacc.org | Akshay S. Desai |Muthiah Vaduganathan |Brian Claggett |Ian J. Kulac
IntroductionHospitalization for management of worsening HF symptoms has long been recognized as a sentinel event with important prognostic implications.
-
Sep 27, 2024 | 
jamanetwork.com | Muthiah Vaduganathan |Brian Claggett |Michele Senni
Key PointsQuestion
What are the long-term expected effects of treatment with the nonsteroidal mineralocorticoid receptor antagonist, finerenone, in patients with heart failure with mildly reduced or preserved ejection fraction?
-
Sep 19, 2024 | 
onlinelibrary.wiley.com | Maria A. Pabon |Muthiah Vaduganathan |Brian Claggett |Safia Chatur
Introduction Heart failure (HF) hospitalizations often signal poor prognosis and are associated with significant healthcare expenses.1 Patients with HF with improved ejection fraction (HFimpEF) have a lower risk of HF hospitalizations as compared to patients with HF with reduced ejection fraction (HFrEF),2 but remain at risk for adverse clinical outcomes.3-7 We have previously shown that about 30% of participants in DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with...
